Case report: complete long-lasting response to multimodal third line treatment with neurosurgical resection, carmustine wafer implantation and dabrafenib plus trametinib in a BRAFV600E mutated high-grade glioma.

病例报告 ： 神经外科切除术对多模式三线治疗的完全持久反应 ，卡莫司汀片植入和达拉非尼联合曲美替尼治疗 BRAFV600E 突变的高级别神经胶质瘤。

• 影响指数: 5.738
• 发表时间: 2024
• 来源期刊: Front Oncol
• DOI: 10.3389/fonc.2024.1359093
• PMID: 38774414
• 文章类型: Case Reports
• 中科院分区: Q2
• 方向: 医学
• 作者列表: Castelli B,Tellini M,Guidi M,Di Nicola M,Giunti L,Buccoliero AM,Censullo ML,Iacono A,Desideri I,Genitori L,Sardi I,Fonte C

关键词: BRAF inhibitors; BRAFV600E; MEK inhibitors; dabrafenib; high-grade glioma; pleomorphic xanthoastrocytoma; target therapy; trametinib

Abstract

Dabrafenib plus trametinib is a promising new therapy for patients affected by BRAFV600E-mutant glioma, with high overall response and manageable toxicity. We described a complete and long-lasting response in a case of recurrent anaplastic pleomorphic xanthoastrocytoma CNS WHO-grade 3 BRAFV600E mutated. Due to very poor prognosis, there are a few described cases of high-grade glioma (HGG) patients treated with the combined target therapy as third-line treatment. The emergence of optimized sequencing strategies and targeted agents, including multimodal and systemic therapy with dabrafenib plus trametinib, will continue to broaden personalized therapy in HGG improving patient outcomes.

摘要

Dabrafenib联合曲美替尼对于BRAFV600E突变神经胶质瘤患者是一种有前途的新疗法，具有较高的总体反应和可控的毒性。我们描述了在复发性间变性多形性黄色星形细胞瘤CNSWHO3级BRAFV600E突变的情况下的完整且持久的反应。由于预后非常差，有少数描述的高级别胶质瘤(HGG)患者接受联合靶向治疗作为三线治疗.优化的测序策略和靶向剂的出现，包括dabrafenib加曲美替尼的多模式和全身治疗，将继续扩大HGG的个性化治疗，以改善患者的预后。